RNAimmune
Gaithersburg
About RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. The company leverages mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. RNAimmune is a spin-off venture from Sirnaomics, Inc. has received a global exclusive right to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery from Sirnaomics. The company has also developed a proprietary A.I. algorithm (ALEPVA) for antigen prediction and vaccine design. By integrating multiple established platform technologies, the company is aiming to develop a comprehensive mRNA drug discovery and development platform, from which the company will enrich its therapeutic and vaccine product pipeline addressing tremendous unmet needs in treatments of viral infections, cancer, and rare diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $39.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2022)
- Website: rnaimmune.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science
Canonical: https://fsome.com/organization/rnaimmune-131355 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.